The MDS Beacon: Genetic Mutations In MDS Persist After Progression To AML
Genetic Mutations In MDS Persist After Progression To Acute Myeloid Leukemia
by Jessica Langholtz
Researchers from Washington University in St. Louis recently discovered that nearly all mutations in the bone marrow cells of patients who progressed from myelodysplastic syndromes to acute myeloid leukemia are derived from mutations that previously existed when the patients had myelodysplastic syndromes.
The study investigators believe that their findings will lead to improvements in diagnostic and prognostic abilities. Specifically, they suggest targeting therapies toward early mutations occurring in the myelodysplastic syndromes (MDS) stage.
For the rest, see the article at MDS Beacon.